The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan.

Abstract:

:The objective of this 12-week, double-masked, randomized, multicenter study was to compare the elastoviscous properties of a high-molecular-weight viscosupplement, hylan G-F 20 (polymer concentration, 0.8%), with those of a lower-molecular-weight hyaluronan (LMW HA) product (polymer concentration, 1%) and to determine the relationship of elastoviscosity to efficacy in the treatment of patients with osteoarthritis (OA) of the knee. Patients had radiographically confirmed primary idiopathic OA of the knee (Larsen grades I to V) with pain despite other treatments. After a 2-week washout period, 70 patients (73 knees) received three 2-mL intra-articular injections of test solution at 1-week intervals. Thirty-eight patients (38 knees) received hylan G-F 20, and 32 patients (35 knees) received LMW HA. During the 12-week follow-up period, the primary outcome measures assessed by patients (using a visual analogue scale) were weight-bearing pain, most painful knee movement, and overall treatment response; the primary outcome measures assessed by study evaluators were weight-bearing pain and overall assessment of treatment. The dynamic elastoviscous properties of the test solutions were measured on an oscillating Couette-type rheometer. Hylan G-F 20 was more elastoviscous than the LMW HA at all frequencies measured (0.001 to 10 Hz). At the final evaluation, patients who received hylan G-F 20 had significantly better results on all primary outcome measures compared with those who received LMW HA. No systemic adverse events were reported. Local adverse events consisted of pain or swelling, noted in 2 of 38 knees injected with hylan G-F 20, and pain, noted in 1 of 35 knees injected with LMW HA (adverse event rates per injection, 1.8% and 0.9%, respectively). The difference in the incidence of adverse events between groups was not statistically significant. The higher-molecular-weight, more elastoviscous hylan G-F 20 had significantly greater pain-relieving effects than did the lower-molecular-weight, less elastoviscous hyaluronan.

journal_name

Clin Ther

journal_title

Clinical therapeutics

authors

Wobig M,Bach G,Beks P,Dickhut A,Runzheimer J,Schwieger G,Vetter G,Balazs E

doi

10.1016/s0149-2918(00)80010-7

subject

Has Abstract

pub_date

1999-09-01 00:00:00

pages

1549-62

issue

9

eissn

0149-2918

issn

1879-114X

pii

S0149291800800107

journal_volume

21

pub_type

临床试验,杂志文章,多中心研究,随机对照试验
  • Unsuccessful cimetidine treatment of peptic ulcer: analysis of the factors involved.

    abstract::Healing rates were examined retrospectively in 124 outpatients with peptic ulcer who had received cimetidine for at least four weeks. Treatment was unsuccessful in 73 patients. A statistical analysis of the factors involved in treatment failure revealed that in patients with duodenal ulcers 60.6% of the treatment succ...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Granelli P,Angelini GP,Celli L

    更新日期:1984-01-01 00:00:00

  • Importance of observational studies in clinical practice.

    abstract:BACKGROUND:In this era of evidence-based medicine, clinicians require a comprehensive range of well-designed studies to support prescribing decisions and patient management. In recent years, data from observational studies have become an increasingly important source of evidence because of improvements in observational...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2007.07.004

    authors: Ligthelm RJ,Borzì V,Gumprecht J,Kawamori R,Wenying Y,Valensi P

    更新日期:2007-06-01 00:00:00

  • A cost-of-illness study of Lyme disease in the United States.

    abstract::Lyme disease produces a diverse clinical picture that can include serious and potentially debilitating cardiac, neurologic, joint, and skin involvement. It is characterized in three stages--early localized (stage I), early disseminated (stage II), and late disseminated (stage III)--and medical management is highly dep...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/s0149-2918(98)80081-7

    authors: Maes E,Lecomte P,Ray N

    更新日期:1998-09-01 00:00:00

  • Pathogen Prevalence and Antimicrobial Susceptibility Among Enterobacteriaceae Causing Hospital-associated Intra-abdominal Infections in Adults in the United States (2012-2013).

    abstract:PURPOSE:Selection and prompt initiation of the appropriate empiric antimicrobial therapy are critical to decrease morbidity and mortality and shorten the length of hospitalization among patients with hospital-associated intra-abdominal infections (HA-IAIs). Therapeutic choices for the treatment of patients with HA-IAI ...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2016.04.035

    authors: Zalacain M,Biedenbach DJ,Badal RE,Young K,Motyl M,Sahm DF

    更新日期:2016-06-01 00:00:00

  • Model-based Voriconazole Dose Optimization in Chinese Adult Patients With Hematologic Malignancies.

    abstract:PURPOSE:The objective of this study was to characterize the population pharmacokinetics of voriconazole and to identify factors that significantly affect pharmacokinetic parameters and to further investigate optimal dosage regimens in Chinese adult patients with hematologic malignancies. METHODS:A prospective populati...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2019.04.027

    authors: Liu Y,Qiu T,Liu Y,Wang J,Hu K,Bao F,Zhang C

    更新日期:2019-06-01 00:00:00

  • Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects.

    abstract:OBJECTIVES:The primary study objective was to assess the time course and intensity of sedation after administration of immediate-release (IR) and extended-release (XR) quetiapine fumarate in healthy subjects during dose initiation. The tolerability of the 2 formulations was also evaluated. METHODS:This was a randomize...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clinthera.2009.03.002

    authors: Datto C,Berggren L,Patel JB,Eriksson H

    更新日期:2009-03-01 00:00:00

  • Evaluation of dronedarone use in the US patient population between 2009 and 2010: a descriptive study using a claims database.

    abstract:BACKGROUND:The utilization pattern of dronedarone was unknown, especially regarding prescribers' compliance with the product's prescribing information (PI) following its availability and the implementation of the Food and Drug Administration-approved risk evaluation and mitigation strategy for the drug in the United St...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2011.08.013

    authors: Gao S,Juhaeri J,Schiappacasse HA,Koren AT,Dai WS

    更新日期:2011-10-01 00:00:00

  • Use of a premixed insulin regimen (Novolin 70/30) to replace self-mixed insulin regimens.

    abstract::The efficacy and safety of transferring 76 patients with poorly controlled type II diabetes mellitus from various self-mixed human insulin regimens to a premixed insulin regimen (Novolin 70/30, 70% NPH and 30% Regular insulin, semisynthetic) were evaluated in a 24-week, multicenter, open-label study. During the initia...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Aronoff S,Goldberg R,Kumar D,Lichtenstein E,Schwartz S,Sosenko J

    更新日期:1994-01-01 00:00:00

  • Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects.

    abstract:PURPOSE:Selumetinib (AZD6244, ARRY-142886), an oral, potent, and highly selective mitogen-activated protein kinase 1/2 inhibitor with a short half-life, has shown activity across various tumor types. Before initiation of Phase III trials, the site, scale, and color (hypromellose shell from white [Phase II] to blue [Pha...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clinthera.2017.08.022

    authors: Tomkinson H,McBride E,Martin P,Lisbon E,Dymond AW,Cantarini M,So K,Holt D

    更新日期:2017-11-01 00:00:00

  • Does type of bolus insulin matter in the hospital? Retrospective cohort analysis of outcomes between patients receiving analogue versus human insulin.

    abstract:BACKGROUND:Poor glycemic control in hospitalized patients has been associated with increased morbidity and mortality. Research suggests that analogue bolus insulin may be more effective in achieving blood glucose (BG) control compared with human bolus insulin. OBJECTIVE:This study compares mortality, length of stay (L...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2010.10.009

    authors: Ko KJ,Tomor V,Nathanson BH,Bouchard JR,Aagren M,Dubois RW

    更新日期:2010-10-01 00:00:00

  • Clinical and Economic Outcomes of Patients with Type 2 Diabetes on Multiple Daily Injections of Basal-bolus Insulin (MDI) Therapy: A Retrospective Cohort Study.

    abstract:PURPOSE:Therapy for patients with type 2 diabetes (T2DM) not achieving hemoglobin (Hb) A1c targets may progress from an oral antidiabetic drug (OAD) to added basal insulin and then to multiple daily injections of basal-bolus insulin (MDI); however, the relative clinical and economic burden experienced by patients presc...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2018.12.014

    authors: Brixner D,Ermakova A,Xiong Y,Sieradzan R,Sacks N,Cyr P,Taylor SD

    更新日期:2019-02-01 00:00:00

  • Pegylated interferons for the treatment of chronic hepatitis C infection.

    abstract:BACKGROUND:Interferon (IFN) alfa is a clinically effective therapy used in a wide range of viral infections and cell-proliferative disorders. Combination therapy with IFN alfa-2b and ribavirin is the current standard of care for the treatment of chronic hepatitis C (CHC) infection. However, standard IFN alfa has the dr...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0149-2918(02)80042-x

    authors: Luxon BA,Grace M,Brassard D,Bordens R

    更新日期:2002-09-01 00:00:00

  • Neuromodulation for the Treatment of Epilepsy: A Review of Current Approaches and Future Directions.

    abstract:PURPOSE:Neuromodulation holds great promise for the treatment of drug-resistant epilepsy. This article reviews the most common types of neuromodulation as well as potential future applications of preclinical techniques such as optogenetics. This review serves as a reference for treating neurologists on the latest scien...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2020.05.017

    authors: Davis P,Gaitanis J

    更新日期:2020-07-01 00:00:00

  • Hemorrhagic cystitis in a patient receiving conventional doses of dacarbazine for metastatic malignant melanoma: case report and review of the literature.

    abstract:INTRODUCTION:Hemorrhagic cystitis is a potentially life-threatening complication in patients receiving cancer therapy. This urologic emergency is commonly associated with the chemotherapeutic use of oxazaphosphorine alkylating agents. This report describes a case of hemorrhagic cystitis associated with dacarbazine trea...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2007.06.004

    authors: Mohammadianpanah M,Shirazi M,Mosalaei A,Omidvari S,Ahmadloo N

    更新日期:2007-06-01 00:00:00

  • Effects of an Extract of Salmon Milt on Symptoms and Serum TNF and Substance P in Patients With Fibromyalgia Syndrome.

    abstract:PURPOSE:The aim of this study was to evaluate the effects of a dietary supplement containing primarily an extract of salmon's milt (semen) on symptoms and blood levels of proinflammatory molecules in patients with fibromyalgia syndrome (FMS), a chronic, painful musculoskeletal disease without a distinct pathogenesis or...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clinthera.2019.05.019

    authors: Tsilioni I,Pipis H,Freitag MSC,Izquierdo MDC,Freitag K,Theoharides TC

    更新日期:2019-08-01 00:00:00

  • Current attitudes on cardiac devices in heart failure: a review.

    abstract:PURPOSE:Despite significant advances in optimizing drug therapy, heart failure-related mortality and morbidity remain high. There has been great progression with regard to device therapy in heart failure, and device use continues to increase. The aims of this review were to critically re-examine the evidence base and t...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2015.08.012

    authors: Marangou J,Paul V

    更新日期:2015-10-01 00:00:00

  • Effect of oral penicillin on pneumococcal carriage in elderly men with chronic bronchitis.

    abstract::A double-blind, randomized, placebo-controlled trial was undertaken to evaluate the effect of penicillin on the pneumococcal carrier state of 32 men with chronic bronchitis. Treatment consisted of 250-mg phenoxymethyl penicillin or placebo tablets taken by mouth twice daily for periods of one to three years. Penicilli...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Haas H,Morris JF,Samson S

    更新日期:1986-01-01 00:00:00

  • Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.

    abstract::In its clinical assessment of the respiratory syncytial virus (RSV)-specific monoclonal antibody palivizumab, the IMpact-RSV Study Group demonstrated a reduction in hospitalizations for RSV-related lower respiratory tract infection in infants who received prophylaxis compared with infants who did not receive prophylax...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/S0149-2918(00)88326-5

    authors: Marchetti A,Lau H,Magar R,Wang L,Devercelli G

    更新日期:1999-04-01 00:00:00

  • The financial impact of OBRA-90 on community pharmacies: an overview.

    abstract::The Omnibus Budget Reconciliation Act of 1990 (OBRA-90) may be the most significant piece of legislation affecting the practice of pharmacy since the Durham-Humphrey amendments to the Food, Drug and Cosmetic Act. As part of the OBRA-90 legislation, the Health Care Financing Administration (HCFA) was required to publis...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Nightengale B,Reeder CE

    更新日期:1993-05-01 00:00:00

  • Clinical and laboratory evaluation of cefoperazone.

    abstract::Cefoperazone, a third-generation cephalosporin derivative, has been reported to have excellent antibacterial activity against a wide range of gram-positive and gram-negative pathogens, including Pseudomonas aeruginosa. We treated 54 patients with a variety of clinical infections with cefoperazone and determined the su...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Sarver DK,Christensen GD,Hester MG,Ling FW,Pate JW,Rosenberg EW,Anderson GD,Bisno AL

    更新日期:1981-01-01 00:00:00

  • Relative Bioavailability of Silybin A and Silybin B From 2 Multiconstituent Dietary Supplement Formulations Containing Milk Thistle Extract: A Single-dose Study.

    abstract:PURPOSE:The purpose of this study was to compare the bioavailability between 2 milk thistle-containing dietary supplements, Product B and IsaGenesis, in healthy volunteers. METHODS:Bioavailability between Product B, originally formulated as a powdered capsule, and IsaGenesis, reformulated as a soft gel, were compared ...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clinthera.2017.11.013

    authors: Li WY,Yu G,Hogan RM,Mohandas R,Frye RF,Gumpricht E,Markowitz JS

    更新日期:2018-01-01 00:00:00

  • In vitro stability of lyophilized and reconstituted recombinant activated factor VII formulated for storage at room temperature.

    abstract:BACKGROUND:Recombinant activated factor VII (rFVIIa) is indicated to treat bleeding episodes or prevent bleeding related to surgery in patients with hemophilia A or B who have antibodies to coagulation factors VIII or IX. The first-generation rFVIIa formulation is stable when stored under refrigeration. A new formulati...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/s0149-2918(08)80055-0

    authors: Nedergaard H,Vestergaard S,Jensen PT,Kristiansen MW,Jensen MB,Ostergaard PB,Norsell T,Bjerre J

    更新日期:2008-07-01 00:00:00

  • A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.

    abstract:BACKGROUND:Oxymorphone extended release (ER) is a tablet formulation of the mu-opioid agonist oxymorphone designed to achieve a low peak-to-trough fluctuation in plasma concentrations over a 12-hour dosing period. OBJECTIVE:This study compared the analgesic efficacy, dose response, and tolerability of 3 doses of oxymo...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clinthera.2006.03.008

    authors: Kivitz A,Ma C,Ahdieh H,Galer BS

    更新日期:2006-03-01 00:00:00

  • Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.

    abstract:PURPOSE:Efavirenz exhibits high interindividual variability in plasma concentrations, leading to unpredictable efficacy and toxicity. Polymorphism of CYP2B6 516G > T has been found to predominantly contribute to efavirenz variability. However, dosage recommendations incorporating CYP2B6 516G > T polymorphism have not b...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2020.04.013

    authors: Chaivichacharn P,Avihingsanon A,Manosuthi W,Ubolyam S,Tongkobpetch S,Shotelersuk V,Punyawudho B

    更新日期:2020-07-01 00:00:00

  • Cost-analysis of imipenem-cilastatin monotherapy compared with clindamycin+aminoglycoside combination therapy for treatment of serious lower respiratory, intra-abdominal, gynecologic, and urinary tract infections.

    abstract::To determine the cost relative to efficacy and tolerability of two antimicrobial regimens, a prospective, multicenter study compared imipenem-cilastatin (I-C) monotherapy with clindamycin+aminoglycoside (C+A) in the treatment of serious lower respiratory, intra-abdominal, gynecologic, and urinary tract infections. The...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Kreter B

    更新日期:1992-01-01 00:00:00

  • Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?

    abstract:PURPOSE:Although recent reports suggest an association between saxagliptin and an increased risk of admissions for heart failure, it is not clear whether dipeptidyl peptidase IV (DPP-IV) inhibition contributes to heart failure in high-risk patients. The purpose of this research is to understand heart failure risk among...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2014.10.009

    authors: Clifton P

    更新日期:2014-12-01 00:00:00

  • Aripiprazole in schizophrenia and schizoaffective disorder: A review.

    abstract:BACKGROUND:During the past decade, there has been some progress in the pharmacotherapy of schizophrenia and schizoaffective disorder. Current evidence supports the use of various second-generation, or atypical, antipsychotic medications, although few of these agents have been associated with long-term efficacy and tole...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2010.01.021

    authors: Stip E,Tourjman V

    更新日期:2010-01-01 00:00:00

  • Midodrine for female incontinence: a preliminary report.

    abstract::Twenty-six women (aged 26 to 60) with stress incontinence underwent urodynamic investigation before and after oral administration of 5 mg of midodrine, a new adrenergic agent with alpha-stimulant activity. A significant increase in maximum urethral closing pressure combined with a nonsignificant increase in flow time ...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Garofalo F,Lalanne GM,Nanni G

    更新日期:1986-01-01 00:00:00

  • Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease.

    abstract:BACKGROUND:Previous health economic studies have demonstrated the cost-effectiveness of simvastatin in the treatment of coronary heart disease (CHD) based on clinical results of the Scandinavian Simvastatin Survival Study. A prior analysis evaluated the "cost of getting to goal," but ignored all costs after titration. ...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/s0149-2918(01)80010-2

    authors: Attanasio E,Russo P,Allen SE

    更新日期:2001-02-01 00:00:00

  • Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials.

    abstract:BACKGROUND:Spinal muscular atrophy (SMA) is an autosomal recessive motor neuron disease caused by mutations in the survival motor neuron gene (SMN1) and the leading genetic cause of infant mortality. Currently, there is no effective treatment other than supportive care. OBJECTIVE:This article provides a general overvi...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2013.11.006

    authors: Zanetta C,Nizzardo M,Simone C,Monguzzi E,Bresolin N,Comi GP,Corti S

    更新日期:2014-01-01 00:00:00